---
title: "RBC Capital Adjusts Price Target on Neurocrine Biosciences to $148 From $154, Keeps Sector Perform Rating"
date: "2025-02-07 23:08:32"
summary: "Neurocrine Biosciences  has an average rating of buy and mean price target of $169.65, according to analysts polled by FactSet."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Neurocrine Biosciences has an average rating of buy and mean price target of $169.65, according to analysts polled by FactSet.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250207:A3312636:0/)
